Compare JPMorgan Chase & Co (JPM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Merck & Co., Inc. — how do they compare? JPMorgan Chase & Co trades at $330.85 (market cap $880.98B), while Merck & Co., Inc. trades at $144.68 (market cap $351.28B). The key difference: JPMorgan Chase & Co is far larger — about 2.5× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Merck & Co., Inc. for 98 Days on average.
| JPM | MRK | |
|---|---|---|
Market Cap | $880.98B | $351.28B |
Volume | 7,721,661 | 7,969,665 |
Sector | Financials | Health |
52-Week High | $365.18 | $156.43 |
52-Week Low | $282.84 | $82.49 |
Typical Hold Time | 127 Days | 98 Days |
Enterprise Value | $1.82T | $398.04B |
Dividend Yield | 1.99% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $329.58, down 0.51% with a bearish technical signal. The stock shows strong fundamentals with revenue growth from $181.85B in 2025 to $194.9B projected for 2026, and a net income margin of 33.38%. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus remains positive with a $373.18 price target. However, negative cash flow trends and geopolitical risks noted by CEO Jamie Dimon present headwinds.
Outlook: JPM offers solid value with a P/E of 14.2 and high ROE of 18.43%, supported by earnings beats and institutional buying. Risks include sustained negative operating cash flow, rising debt-to-asset ratio (11.34% in 2024), and macroeconomic volatility. The stock is a hold for long-term investors, with upside to consensus target if earnings momentum continues.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
